Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus CEFTAZIDIME SODIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus CEFTAZIDIME SODIUM IN PLASTIC CONTAINER.
ANSPOR vs CEFTAZIDIME SODIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic